🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11 results for “Almirall, S.A.” Clear

  1. Ebglyss 250 mg solution for injection in pre-filled syringe, Placebo, Ebglyss 250 mg solution for injection in pre-filled pen

    Almirall, S.A.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  2. Placebo, Ebglyss 250 mg solution for injection in pre-filled syringe

    Almirall, S.A.

    Nummular Dermatitis

    phase 3 small molecule active

    1 trial

  3. TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment

    Almirall, S.A.

    Actinic Keratosis on the Face or Scalp

    phase 3 small molecule active

    1 trial

  4. LAD328, SODIUM CHLORIDE

    Almirall, S.A.

    moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  5. Placebo for LAD603, LAD603

    Almirall, S.A.

    Alopecia areata

    phase 2 small molecule active

    1 trial

  6. SODIUM CHLORIDE, ADALIMUMAB, LAD191, LAD191 placebo

    Almirall, S.A.

    Moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  7. A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers.

    Almirall, S.A.

    Inflammatory diseases

    phase 1 other active

    1 trial

  8. Almax Forte 1,5 g suspensión oral

    Almirall, S.A.

    heartburn and or reflux

    approved small molecule active

    1 trial

  9. Klisyri 10 mg/g ointment, Solaraze 30 mg/g Gel

    Almirall, S.A.

    Actinic Keratosis

    approved small molecule active

    1 trial

  10. Pidotimod

    Almirall, S.A.

    Recurrent Respiratory Tract Infections

    approved small molecule completed

    1 trial

  11. Toujeo

    Almirall, S.A.

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources